NYSE:BSX - Boston Scientific Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$32.78 +0.63 (+1.96 %)
(As of 06/22/2018 02:37 PM ET)
Previous Close$32.32
Today's Range$32.22 - $33.03
52-Week Range$24.54 - $37.30
Volume313,758 shs
Average Volume9.71 million shs
Market Capitalization$44.47 billion
P/E Ratio26.05
Dividend YieldN/A
Boston Scientific logoBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.68
Current Ratio0.82
Quick Ratio0.59


Trailing P/E Ratio26.05
Forward P/E Ratio23.58
P/E Growth2.3

Sales & Book Value

Annual Sales$9.05 billion
Price / Sales5.00
Cash Flow$1.9260 per share
Price / Cash17.02
Book Value$5.11 per share
Price / Book6.41


EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins1.21%
Return on Equity25.10%
Return on Assets9.63%


Outstanding Shares1,379,810,000

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) released its quarterly earnings data on Wednesday, April, 25th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.01. The medical equipment provider had revenue of $2.38 billion for the quarter, compared to analysts' expectations of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. Boston Scientific's quarterly revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.29 earnings per share. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus estimate of $1.37. The company issued revenue guidance of $9.75-9.90 billion (+5-7% organic), compared to the consensus revenue estimate of $9.75 billion.Boston Scientific also updated its Q2 guidance to $0.33-0.35 EPS.

What price target have analysts set for BSX?

21 brokers have issued 1-year target prices for Boston Scientific's shares. Their forecasts range from $27.00 to $36.00. On average, they anticipate Boston Scientific's share price to reach $32.3810 in the next twelve months. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. According to Zacks Investment Research, "Boston Scientific posted an impressive first quarter on growth across all business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. During the quarter, Boston Scientific announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. This inorganic expansion plan bode well for the stocks operational growth. Over the past three months, Boston Scientific outperformed its industry. On the flip side, a delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too." (5/30/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)

Has Boston Scientific been receiving favorable news coverage?

News stories about BSX stock have trended somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Boston Scientific earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 44.28 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.70%), Bollard Group LLC (2.44%), Artisan Partners Limited Partnership (1.94%), Northern Trust Corp (1.08%), Wells Fargo & Company MN (0.93%) and Newport Trust Co (0.78%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Boston Partners, Artisan Partners Limited Partnership, Prudential Financial Inc., State of Tennessee Treasury Department, Natixis, Russell Investments Group Ltd. and Swiss National Bank. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

Which major investors are buying Boston Scientific stock?

BSX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Eaton Vance Management, Cannell Peter B & Co. Inc., Bodenholm Capital AB, Point72 Asset Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC and Royal Bank of Canada. View Insider Buying and Selling for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $32.91.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $44.47 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  643 (Vote Outperform)
Underperform Votes:  576 (Vote Underperform)
Total Votes:  1,219
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.